Prednisolone- and sirolimus-eluting stent: Anti-inflammatory approach for inhibiting in-stent restenosis

Abstract

Glucocorticoids are powerful anti-inflammatory, immunosuppressive, and anti-proliferative agents. The aim of this study was to evaluate the effectiveness of a prednisolone- (PDScs) and sirolimus-coated stent (SRLcs) in preventing artery vessel neointimal hyperplasia and inflammatory reactions in vitro and in vivo. PDS, a synthetic glucocorticoid, is a derivative of cortisol, which is used to treat a variety of inflammatory and autoimmune conditions. The stents were fabricated with PDS, SRL, or both agents using a layer-by-layer coating system (designated as PDScs, SRLcs, and PDSRLcs, respectively). The surface morphology of the PDScs showed an evenly dispersed and roughened shape, which was smoothened by the SRL coating. Half of the total drug amounts were released within seven days, followed by an additional release, which continued for up to 28 days. The proliferation of smooth muscle cells was inhibited in the SRLcs group (31.5 ± 4.08%), and this effect was enhanced by PDS addition (PDSRLcs, 46.8 ± 8.11%). Consistently, in the animal study, the restenosis rate was inhibited by the SRLcs and PDSRLcs (18.5 ± 6.23% and 14.5 ± 3.55%, respectively). Especially, fibrin expression and inflammation were suppressed in the PDS-containing group (PDScs, 0.6 ± 0.12 and 1.4 ± 0.33; PDSRLcs, 0.7 ± 0.48 and 1.7 ± 0.12, respectively) compared to PDS non-containing groups (BMS, 1.1 ± 0.12, and 1.8 ± 0.55; SRLcs, 1.6 ± 0.32 and 2.0 ± 0.62, respectively). Moreover, re-endothelialization was enhanced in the PDScs group as determined using immunohistochemistry with a cluster of differentiation (CD)-31 antibodies. These results suggest that the inhibitory effect of SRLcs on anti-restenosis can be accelerated by additional coating with PDS, which has promising properties as a bioactive compound with useful anti-inflammatory effects.

Keywords

Prednisolone sirolimus drug-eluting stent anti-restenosis anti-inflammation

Get full access to this article

View all access options for this article.

References

Dibra

Kastrati

Alfonso

. Effectiveness of drug-eluting stents in patients with bare-metal in-stent restenosis: meta-analysis of randomized trials. J Am Coll Cardiol 2007; 49: 616–623.

Scott

. Restenosis following implantation of bare metal coronary stents: pathophysiology and pathways involved in the vascular response to injury. Adv Drug Deliv Rev 2006; 58: 358–376.

Tung

Kaul

Diamond

. Narrative review: drug-eluting stents for the management of restenosis: a critical appraisal of the evidence. Ann Intern Med 2006; 144: 913–919.

Abizaid

Costa

Jr Banning

. The sirolimus-eluting Cypher Select coronary stent for the treatment of bare-metal and drug-eluting stent restenosis: insights from the e-SELECT (Multicenter Post-Market Surveillance) registry. JACC Cardiovasc Interv 2012; 5: 64–71.

Windecker

Haude

Neumann

. Comparison of a novel biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: results of the randomized BIOFLOW-II Trial. Circ Cardiovasc Interv 2015; 8: e001441–e001441.

Blazek

Rossbach

Borger

. Comparison of sirolimus-eluting stenting with minimally invasive bypass surgery for stenosis of the left anterior descending coronary artery: 7-year follow-up of a randomized trial. JACC Cardiovasc Interv 2015; 8: 30–38.

Farb

Weber

Kolodgie

. Morphological predictors of restenosis after coronary stenting in humans. Circulation 2002; 105: 2974–2980.

Moreno

Bernardi

Lopez-Cuellar

. Macrophage infiltration predicts restenosis after coronary intervention in patients with unstable angina. Circulation 1996; 94: 3098–3102.

Macdonald

Panush

Pepine

. Rationale for use of glucocorticoids in modification of restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol 1987; 60: 56B–60B.

10.

Liu

De Scheerder

Desmet

. Dexamethasone-eluting stent: an anti-inflammatory approach to inhibit coronary restenosis. Expert Rev Cardiovasc Ther 2004; 2: 653–660.

11.

Ribichini

Tomai

Ferrero

. Immunosuppressive oral prednisone after percutaneous interventions in patients with multi-vessel coronary artery disease. The IMPRESS-2/MVD study. EuroIntervention 2005; 1: 173–180.

12.

Ferrero

Tomai

Versaci

. Long-term results of immunosuppressive oral prednisone after coronary angioplasty in non-diabetic patients with elevated C-reactive protein levels. EuroIntervention 2009; 5: 250–254.

13.

Versaci

Gaspardone

Tomai

. Immunosuppressive therapy for the prevention of restenosis after coronary artery stent implantation (IMPRESS Study). J Am Coll Cardiol 2002; 40: 1935–1942.

14.

Berk

Gordon

Alexander

. Pharmacologic roles of heparin and glucocorticoids to prevent restenosis after coronary angioplasty. J Am Coll Cardiol 1991; 17: 111B–117B.

15.

Reil

Sarkar

Kashyap

. Dexamethasone suppresses vascular smooth muscle cell proliferation. J Surg Res 1999; 85: 109–114.

16.

Ribichini

Joner

Ferrero

. Effects of oral prednisone after stenting in a rabbit model of established atherosclerosis. J Am Coll Cardiol 2007; 50: 176–185.

17.

Buszman

Trznadel

Zurakowski

. Prospective registry evaluating safety and efficacy of cobalt-chromium stent implantation in patients with de novo coronary lesions. Kardiol Pol 2007; 65: 1041–1046. discussion 1047–1048.

18.

Oyamada

Gao

. Paclitaxel/sirolimus combination coated drug-eluting stent: in vitro and in vivo drug release studies. J Pharm Biomed Anal 2011; 54: 807–811.

19.

Schwartz

Edelman

Virmani

. Drug-eluting stents in preclinical studies: updated consensus recommendations for preclinical evaluation. Circ Cardiovasc Interv 2008; 1: 143–153.

20.

Topol

Jiang

Choi

. Wnt-5a inhibits the canonical Wnt pathway by promoting GSK-3-independent beta-catenin degradation. J Cell Biol 2003; 162: 899–908.

21.

Heldman

Cheng

Jenkins

. Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis. Circulation 2001; 103: 2289–2295.

22.

Lim

Bae

Kim

. Mechanical and histopathological comparison between commercialized and newly designed coronary bare metal stents in a porcine coronary restenosis model. Chonnam Med J 2013; 49: 7–13.

23.

Bae

Lim

Park

. Mechanical behavior and in vivo properties of newly designed bare metal stent for enhanced flexibility. J Ind Eng Chem 2015; 21: 1295–1300.

24.

Coutinho

Chapman

. The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol Cell Endocrinol 2011; 335: 2–3.

25.

Vetrovec

Rizik

Williard

. Sirolimus PK trial: a pharmacokinetic study of the sirolimus-eluting Bx velocity stent in patients with de novo coronary lesions. Catheter Cardiovasc Interv 2006; 67: 32–37.

26.

Seidel

. Cellular heterogeneity of the vascular tunica media. Implications for vessel wall repair. Arterioscler Thromb Vasc Biol 1997; 17: 1868–1871.

27.

Ribichini

Tomai

Pesarini

. Long-term clinical follow-up of the multicentre, randomized study to test immunosuppressive therapy with oral prednisone for the prevention of restenosis after percutaneous coronary interventions: cortisone plus BMS or DES veRsus BMS alone to EliminAte Restenosis (CEREA-DES). Eur Heart J 2013; 34: 1740–1748.

28.

Joner

Morimoto

Kasukawa

. Site-specific targeting of nanoparticle prednisolone reduces in-stent restenosis in a rabbit model of established atheroma. Arterioscler Thromb Vasc Biol 2008; 28: 1960–1966.

29.

Guo

Wang

. In vivo evaluation of a novel dexamethasone-heparin-double-coated stent for inhibition of artery restenosis and thrombosis. J Mater Sci Mater Med 2011; 22: 1615–1623.

30.

Hamalainen

Nieminen

Uurto

. Dexamethasone-eluting vascular stents. Basic Clin Pharmacol Toxicol 2013; 112: 296–301.